Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. The concordance of the relative abundance of mutations in plasma ctDNA with cancer recurrence.
In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including: 1. st: 10 Days after patients received radical resection. 2. nd: When patients finished the chemotherapy or target drug delivery two cycles. 3. rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles. 4. th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA).
Study Type
OBSERVATIONAL
Enrollment
200
Beijing Hospital
Beijing, Beijing Municipality, China
RECRUITINGCancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
RECRUITINGTumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection.
The tumor molecular clones and the frequency of gene mutations from 1021 tumor related genes will be detected by next-generation sequencing, which will be matched with the CT scanning.
Time frame: From assignment of the first subject to the time point when tumor recrudescence or 2 years after radical resection. The last participant will be recruited before June 30,2021.
The concordance of the plasma ctDNA detection status with Progress Free Survival (PFS) and Overall Survival (OS) after radical resection or/and under adjuvant therapy.
Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy.
Time frame: From assignment of the first subject to the time point when tumor recrudescence or 2 years after radical resection. The last participant will be recruited before June 30, 2021.
Evaluation of ctDNA detecting assay in monitoring recurrence of early stage of lung cancer after radical resection.
All the patients will receive biopsy genotype assay and ctDNA liquid biopsy.
Time frame: From assignment of the first subject to the time point when tumor recrudescence or 2 years after radical resection. The last participant will be recruited before June 30, 2021.
The molecular mechanism between the tumor recurrence and ctDNA mutations
Time frame: From assignment of the first subject to the time point when tumor recrudescence or 2 years after radical resection. The last participant will be recruited before June 30, 2021.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
RECRUITINGBeijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGXuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGBeijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGFourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
RECRUITINGHebei General Hospital
Shijiazhuang, Hebei, China
RECRUITINGTangshan People's Hospital
Tangshan, Hebei, China
RECRUITINGThe First Bethune Hospital of Jilin University
Changchun, Jilin, China
RECRUITING